Why IDEXX Laboratories (IDXX) Stock Is Down Today

IDEXX Laboratories (IDXX) is down 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The sell-off does not appear tied to a new negative filing or operating update from IDEXX itself. This could be because investors are reacting to a stronger competitive backdrop in veterinary diagnostics, ongoing caution around clinic traffic trends in pet care, and the stock’s still-rich valuation ahead of IDEXX’s August 4, 2026 earnings report.

Details:

IDEXX’s investor relations page shows its next major catalyst is second-quarter results on August 4, 2026, and its latest news item was the July 1 notice setting that release date rather than a business setback.

The company’s SEC filings list does not show a fresh July current report on the front page, suggesting there was no obvious new company-specific disclosure driving the drop.

In first-quarter 2026 results, IDEXX posted 14% revenue growth and 17% EPS growth, while also raising full-year guidance, so today’s decline looks more sentiment-driven than a reversal in recently reported fundamentals.

IDEXX has also warned that pet healthcare demand can still be affected by macro conditions and clinical visit pressure, and a rival announced a diagnostics-focused acquisition today that may have sharpened competitive concerns across the space.

Sources:

IDEXX Investor Relations, SEC, Zoetis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IDXX Insider Trading Activity

$IDXX insiders have traded $IDXX stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.

Here’s a breakdown of recent trading of $IDXX stock by insiders over the last 6 months:

JONATHAN JAY MAZELSKY (President and CEO) has made 0 purchases and 13 sales selling 23,326 shares for an estimated $15,338,080.
GEORGE FENNELL (Executive Vice President) has made 0 purchases and 8 sales selling 11,345 shares for an estimated $7,336,993.
MICHAEL G ERICKSON (Executive Vice President) has made 0 purchases and 6 sales selling 5,371 shares for an estimated $3,369,666.
NIMRATA HUNT (Executive Vice President) has made 0 purchases and 2 sales selling 4,451 shares for an estimated $2,897,107.
SOPHIE V. VANDEBROEK has made 0 purchases and 2 sales selling 1,464 shares for an estimated $920,293.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$IDXX Hedge Fund Activity

We have seen 476 institutional investors add shares of $IDXX stock to their portfolio, and 634 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ELYXIUM WEALTH, LLC removed 5,406,536 shares (-99.8%) from their portfolio in Q1 2026, for an estimated $3,037,878,513
J. STERN & CO. LLP removed 2,648,665 shares (-99.8%) from their portfolio in Q1 2026, for an estimated $1,488,258,376
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 1,441,696 shares (-99.8%) from their portfolio in Q1 2026, for an estimated $810,074,565
CAPITAL WORLD INVESTORS added 497,851 shares (+inf%) to their portfolio in Q1 2026, for an estimated $279,737,498
FUNDSMITH LLP removed 410,249 shares (-21.9%) from their portfolio in Q1 2026, for an estimated $230,514,810
PRICE T ROWE ASSOCIATES INC /MD/ removed 314,160 shares (-33.0%) from their portfolio in Q1 2026, for an estimated $176,523,362
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 288,471 shares (+52.4%) to their portfolio in Q1 2026, for an estimated $162,088,970

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$IDXX Congressional Stock Trading

Members of Congress have traded $IDXX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $IDXX stock by members of Congress over the last 6 months:

REPRESENTATIVE APRIL MCCLAIN DELANEY sold up to $15,000 on 01/13.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$IDXX Analyst Ratings

Wall Street analysts have issued reports on $IDXX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 02/03/2026

To track analyst ratings and price targets for $IDXX, check out Quiver Quantitative's $IDXX forecast page.

$IDXX Price Targets

Multiple analysts have issued price targets for $IDXX recently. We have seen 6 analysts offer price targets for $IDXX in the last 6 months, with a median target of $712.5.

Here are some recent targets:

Andrea Alfonso from UBS set a target price of $640.0 on 04/28/2026
Daniel Grosslight from Citigroup set a target price of $650.0 on 04/15/2026
Jonathan Block from Stifel set a target price of $675.0 on 03/31/2026
David Westenberg from Piper Sandler set a target price of $750.0 on 02/09/2026
Glen Santangelo from Barclays set a target price of $800.0 on 02/05/2026
Mark Massaro from BTIG set a target price of $800.0 on 02/03/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.